for Journals by Title or ISSN
for Articles by Keywords
help
Followed Journals
Journal you Follow: 0
 
Sign Up to follow journals, search in your chosen journals and, optionally, receive Email Alerts when new issues of your Followed Journals are published.
Already have an account? Sign In to see the journals you follow.
Journal Cover The Medical Letter
  [SJR: 0.314]   [H-I: 16]   [8 followers]  Follow
    
   Full-text available via subscription Subscription journal  (Not entitled to full-text)
   ISSN (Print) 0025-732X - ISSN (Online) 1523-2859
   Published by The Medical Letter, Inc Homepage  [1 journal]
  • In Brief: New Adult Immunization Recommendations
    • Authors: admin
      Abstract: Date:  April 24, 2017 Issue #:  1519 Summary:  The 2017 adult immunization schedule approved by the CDC's Advisory Committee on Immunization Practices (ACIP) includes some new or revised recommendations.1 The complete schedule is available on the CDC's website (www.cdc.gov/vaccines/schedule). New recommendations for use of influenza vaccine during the 2016-2017 season were included in a previous issue of The Medical Letter.2 Updated recommendations for other vaccines are summarized below. Recommendations for routine use of vaccines in adults were reviewed in an earlier issue.3


      DK Kim et al. Advisory Committee on Immunization Practices recommended immunization schedule for adults aged 19 years or older – United States, 2017. MMWR Morb Mortal Wkly Rep 2017; 66:136.
      Influenza vaccine for 2016-2017. Med Lett Drugs Ther 2016; 58:127.
      Adult immunization. Treat Guidel Med Lett 2014; 12:39.
      Gardasil 9 – a broader HPV vaccine. Med Lett Drugs Ther 2015; 57:47.
      Trumenba: a serogroup B meningococcal vaccine. Med Lett Drugs Ther 2015; 57:5.
      Bexsero – a second serogroup B meningococcal vaccine. Med Lett Drugs Ther 2015; 57:158.

      Download complete U.S. English article


      PubDate: Tue, 18 Apr 2017 12:58:31 +000
       
  • Arymo ER - A New Abuse-Deterrent Morphine Formulation
    • Authors: admin
      Abstract: Date:  April 24, 2017 Issue #:  1519 Summary:  The FDA has approved Arymo ER (Egalet), a newextended-release, abuse-deterrent tablet formulationof morphine sulfate, for management of pain severeenough to require daily, around-the-clock, long-termopioid treatment and for which alternative treatmentoptions are inadequate. Arymo ER can only bemarketed to deter abuse by injection because anothersingle-entity, extended-release morphine product,MorphaBond, which has not been marketed to date,has marketing exclusivity for deterrence of abuse bythe intranasal route through October 2018.
      PubDate: Tue, 18 Apr 2017 12:34:26 +000
       
  • Reduction of Cardiovascular Risk with Evolocumab (Repatha)
    • Authors: admin
      Abstract: Date:  April 24, 2017 Issue #:  1519 Summary:  The results of the recently published FOURIER trialhave shown a reduction in cardiovascular events withaddition of the PCSK9 inhibitor evolocumab (Repatha)to statin therapy in patients with atheroscleroticcardiovascular disease (ASCVD).
      PubDate: Mon, 17 Apr 2017 18:45:14 +000
       
  • Dupilumab (Dupixent) for Moderate to Severe Atopic Dermatitis
    • Authors: admin
      Abstract: Date:  April 24, 2017 Issue #:  1519 Summary:  The FDA has approved dupilumab (Dupixent – Sanofi/Regeneron), a subcutaneously-injected fully humanmonoclonal antibody, for treatment of adults withmoderate to severe atopic dermatitis (eczema) thathas not responded to topical therapies. It can be usedwith or without topical corticosteroids.
      PubDate: Wed, 22 Mar 2017 11:54:14 +000
       
  • Plecanatide (Trulance) for Chronic Idiopathic Constipation
    • Authors: admin
      Abstract: Date:  April 24, 2017 Issue #:  1519 Summary:  The FDA has approved plecanatide (Trulance –Synergy), a guanylate cyclase-C receptor agonist,for treatment of chronic idiopathic constipation (CIC)in adults. Linaclotide (Linzess), another guanylatecyclase-C receptor agonist, and lubiprostone (Amitiza),a chloride channel activator, were approved earlier fortreatment of CIC in adults.
      PubDate: Wed, 22 Mar 2017 11:53:39 +000
       
  • In Brief: Pancreatitis with Eluxadoline (Viberzi) in Patients without a
           Gallbladder
    • Authors: admin
      Abstract: Date:  April 24, 2017 Issue #:  1519 Summary:  The FDA has warned that eluxadoline (Viberzi – Allergan), a mu-opioid receptor agonist and delta-opioid receptor antagonist approved in 2015 for treatment of irritable bowel syndrome with diarrhea (IBS-D),1 should not be used in patients without a gallbladder because of an increased risk of serious pancreatitis.2

      As of February 2017, the FDA had received reports of 118 cases of serious, nonfatal pancreatitis and 2 deaths associated with use of eluxadoline. Both deaths occurred in patients without a gallbladder who developed severe abdominal pain and vomiting shortly after taking the first dose. At least 48 of the cases occurred after only 1 or 2 doses of eluxadoline. Of the 68 patients whose gallbladder status was reported, 56 did not have a gallbladder. Most of the patients without a gallbladder (44/56) were taking the reduced dosage of eluxadoline recommended for such patients (75 mg once/day).

      Patients considered at risk for pancreatitis were excluded from the two trials that led to approval of eluxadoline. One case of pancreatitis and 8 cases of abdominal pain with hepatic enzyme elevation associated with sphincter of Oddi spasm occurred with use of eluxadoline in the trials, all in patients without a gallbladder.3

      According to the current label, eluxadoline is contraindicated in patients who abuse alcohol (including those who consume >3 servings of alcohol per day) and in those with known or suspected biliary duct, pancreatic duct, or GI tract obstruction, sphincter of Oddi disease or dysfunction, or severe hepatic impairment (Child-Pugh C). It is also contraindicated in those with a history of pancreatitis, structural pancreatic disease, or chronic or severe constipation.

      Some alternatives to eluxadoline, which is only modestly more effective than placebo in relieving IBS-D symptoms, are the antidiarrheal loperamide (Imodium, and generics), the non-absorbed antibiotic rifaximin (Xifaxan), and the 5-HT3 receptor antagonist alosetron (Lotronex, and generics). Taken as needed, loperamide can reduce postprandial urgency and stool frequency, but it does not improve global symptoms of IBS-D. Like eluxadoline, rifaximin has only been modestly effective in relieving symptoms. Because of concerns about severe constipation and ischemic colitis, alosetron should be used only in women with severe, chronic IBS-D that is unresponsive to other drugs.4


      Eluxadoline (Viberzi) for irritable bowel syndrome with diarrhea. Med Lett Drugs Ther 2016; 58:4.
      FDA Drug Safety Communication: FDA warns about increased risk of serious pancreatitis with irritable bowel drug Viberzi (eluxadoline) in patients without a gallbladder. Available at: www.fda.gov. Accessed April 13, 2017.
      AJ Lembo et al. Eluxadoline for irritable bowel syndrome with diarrhea. N Engl J Med 2016; 374:242.
      Drugs for irritable bowel syndrome. Med Lett Drugs Ther 2016; 58:121.

      Download complete U.S. English article


      PubDate: Wed, 22 Mar 2017 11:52:46 +000
       
  • OTC Fluticasone Furoate Nasal Spray (Flonase Sensimist) for Allergic
           Rhinitis (online only)
    • Authors: admin
      Abstract: Date:  April 24, 2017 Issue #:  1519 Summary:  The nasal spray formulation of the corticosteroidfluticasone furoate is now available over thecounter (OTC) as Flonase Sensimist Allergy Relief(GSK) in the same strength as the prescriptionproduct (Veramyst) for treatment of seasonal orperennial allergic rhinitis. It is the fourth intranasalcorticosteroid to become available OTC.
      PubDate: Wed, 22 Mar 2017 11:51:54 +000
       
 
 
JournalTOCs
School of Mathematical and Computer Sciences
Heriot-Watt University
Edinburgh, EH14 4AS, UK
Email: journaltocs@hw.ac.uk
Tel: +00 44 (0)131 4513762
Fax: +00 44 (0)131 4513327
 
Home (Search)
Subjects A-Z
Publishers A-Z
Customise
APIs
Your IP address: 54.145.108.181
 
About JournalTOCs
API
Help
News (blog, publications)
JournalTOCs on Twitter   JournalTOCs on Facebook

JournalTOCs © 2009-2016